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Li-Fraumeni syndrome (LFS) is a rare autosomal dominant condition with incomplete penetrance that increases an affected person's risk of developing any of a variety of tumours. '5 Members of these families have an increased risk of childhood sarcoma, premenopausal breast cancer, leukaemia, brain tumours, osteo-11 III IV V sarcomas, and adrenocortical carcinomas. Other tumours possibly associated with this syndrome include melanoma, carcinomas of lung, pancreas, and prostate, and gonadal germ cell tumours.' LFS was first described in 1969' and is associated with germline mutations of the tumour suppressor gene p53.5-9 Although second malignant neoplasms have been described in children with p53 mutations,7 two simultaneous but embryologically different tumours have not been reported previously.
We report the case of a 20 month old white female with a germline p53 mutation and Turner syndrome, who was diagnosed with both metastatic adrenocortical carcinoma and ganglioneuroblastoma.
Case report The proband was born after 35 weeks of gestation to non-consanguineous, 28 congestive heart failure from a high flow nodule ( fig 5) and a right adrenal mass, respectively. A CT scan of the head, neck, and pelvis was normal, as was a bone scan. Microscopic examination of the bone marrow aspirate obtained from both iliac crests was normal. A laparotomy followed by a thoracotomy resulted in complete resection of the tumour and showed two histologically distinct right adrenal tumours: adrenocortical carcinoma (ACC) and ganglioneuroblastoma (GNB) with the former metastasising to the lung (figs 6, 7, and 8 Adrenocortical carcinoma has been previously reported in association with p53 abnormalities." 12 However, to the best of our knowledge, this is the first report of two embryologically distinct tumours occurring simultaneously in a patient with abnormalities of the p53 gene.
The known association between mutations of the p53 gene and childhood adrenocortical carcinoma5 611 12 prompted us to examine our patient for germline p53 mutations. A single substitution was found at codon 248 of exon 7. Most germline p53 mutations found in patients with Li-Fraumeni syndrome occur between exons 5 and 8, in codons 110 to 307. " A mutational "hot spot" at the CpG dinucleotide moiety of codon 248 affected four of eight families described in one report. 6 Neuroblastomas and ganglioneuroblastomas originate from embryonic neural crest derived cells. The true incidence of these tumours is unknown because many spontaneously regress. Neuroblastoma was not documented in the original families characterised by Li and Fraumeni.' However, Malkin et af reported one patient with a germline p53 mutation in codon 248 who developed breast cancer after surviving neuroblastoma at 1 year of age. Davidoff et al"4 examined five neuroblastoma derived cell lines for p53 protein expression and found that four of these lines expressed high levels of this protein. The p53 gene was sequenced between codons 125 and 290 in these four lines and found to be normal wild type sequence. The authors surmised that this high level of p53 expression may reflect the embryonic origin of these tumours. No relation between the transformation of these cell lines and p53 could be determined. To our knowledge, p53 mutations have not been reported in isolated cases of neuroblastoma.
A number of investigators have suggested an association between neuroblastoma and conotruncal defects of the heart on the basis of aberrant neural crest migration and development. '5 16 However, this association has been reported in only about 20 previous cases and none of these have had coarctation as part of their cardiovascular anomalies.'6 On the other hand, coarctation has been a well described anomaly associated with sex chromosome aneuploidy. [17] [18] [19] [20] A similar embryological basis for these cardiovascular anomalies in patients with TS has been proposed.2' In our particular patient, neuroblastoma, TS, and coarctation may be interrelated. 
